Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients

Alicja Bartkowska-Śniatkowska1, Agnieszka Bienert2, Paweł Wiczling3

  • 1Department of Pediatric Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland.

Insights

This study developed a population pharmacokinetic model for sufentanil in critically ill children. Dosing adjustments based on body weight are recommended to maintain consistent plasma concentrations.

Area of Science:

  • Pharmacology
  • Pediatric Intensive Care
  • Pharmacokinetics

Background:

  • Sufentanil is commonly used for analgesia and sedation in pediatric intensive care units.
  • Understanding sufentanil pharmacokinetics (PK) in critically ill children is crucial for optimizing dosing.
  • Population PK modeling can characterize drug disposition and identify factors influencing variability.

Purpose of the Study:

  • To develop a population pharmacokinetic model for sufentanil in critically ill children.
  • To evaluate the impact of covariates on sufentanil PK in this population.
  • To provide a basis for weight-based dosing recommendations.

Main Methods:

  • Population nonlinear mixed-effects modeling using NONMEM.
  • Analysis of blood samples from 41 critically ill children.
  • Application of allometric/isometric principles for PK parameter scaling.

Main Results:

  • A two-compartment model adequately described sufentanil PK.
  • High interindividual variability was observed for all PK parameters.
  • A weight-based formula was derived to adjust infusion rates for pediatric patients.

Conclusions:

  • The developed population PK model provides insights into sufentanil disposition in critically ill children.
  • Body weight is a significant factor for adjusting sufentanil infusion rates.
  • Covariates such as illness severity and vasopressor use did not significantly influence sufentanil PK.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
383
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
786
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
489
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
346
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
380
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
842